Biogen (BIIB) PT Lowered to $231 as RBC Capital Sees 'Attractive Entry Point for Shares'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $231.00 (from $260.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
